<prompt> True about BCR-ABL trials are all except:P190 has an indolent courseP190 is a bad prognostic factorP230 is positive in chronic neutrophilic leukemiaP230 has an indolent course  <response>: BCR- ABL fusion is responsible for form action of Tyrosine kinase enzyme. Variant of Tyrosine kinase:- 1 190 k Da:- seen in B-ALL 2 210 KDa:- seen in CML 3 230 KDa:- seen in CNL chronic neutrophilic leukemia Aggressiveness of cancer based on size of Tyrosine kinase :- 190 210230 KDa. 190 KDa seen in B-ALL :- most aggressive course B-ALL with translocation 9:22 has bad prognosis 230 KDa :- least aggressive course indolent course 